Patent · US Active

Compositions and methods for using engineered deubiquitinases for probing ubiquitin-dependent cellular processes

US12091695B2 · kind B2 · utility

1Cited by

0References

30Claims

0Family size

Assignee

The Trustees of Columbia University in the City of New York · US

Inventors

Henry M. Colecraft · Pages Corner, US
Scott Kanner · New York, US

Key dates

Filing date	Nov 3, 2023
Grant date	Sep 17, 2024
Priority date	—
Expiry date	Nov 3, 2043

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/382
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure provides, inter alia, a recombinant engineered deubiquitinase (DUB) and methods for treating or ameliorating an inherited ion channelopathy, such as long QT syndrome, Brugada syndrome, or cystic fibrosis, in a subject. Further provided are methods for screening mutations causing such inherited ion channelopathies for a trafficking-deficient mutation that is treatable by the recombinant engineered DUB disclosed herein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.